Alfacip: Advanced Vitamin D Therapy for Optimal Bone Health
Alfacip
| Product dosage: 0.25 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $2.17 | $65.00 (0%) | 🛒 Add to cart |
| 60 | $1.98 | $130.00 $119.00 (8%) | 🛒 Add to cart |
| 120 | $1.88 | $260.00 $225.00 (13%) | 🛒 Add to cart |
| 240 | $1.82 | $520.00 $438.00 (16%) | 🛒 Add to cart |
| 300 | $1.81
Best per cap | $650.00 $544.00 (16%) | 🛒 Add to cart |
| Product dosage: 0.5 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $2.23 | $67.00 (0%) | 🛒 Add to cart |
| 60 | $2.03 | $134.00 $122.00 (9%) | 🛒 Add to cart |
| 120 | $1.94 | $268.00 $233.00 (13%) | 🛒 Add to cart |
| 240 | $1.89 | $536.00 $453.00 (15%) | 🛒 Add to cart |
| 300 | $1.88
Best per cap | $670.00 $563.00 (16%) | 🛒 Add to cart |
Synonyms | |||
Alfacip is a high-potency prescription medication containing the active form of Vitamin D, calcitriol, designed to manage and prevent conditions associated with calcium and phosphate metabolism disorders. It is specifically indicated for patients with chronic kidney disease, hypoparathyroidism, and certain types of rickets or osteomalacia where endogenous Vitamin D synthesis or activation is impaired. By directly providing biologically active calcitriol, Alfacip ensures efficient intestinal calcium absorption, promotes bone mineralization, and helps maintain serum calcium levels within the physiological range, reducing the risk of skeletal complications and supporting overall metabolic balance.
Features
- Contains calcitriol (1,25-dihydroxycholecalciferol), the hormonally active form of Vitamin D
- Available in soft gelatin capsules for precise oral dosing
- Manufactured under strict pharmaceutical quality controls
- Formulated for enhanced bioavailability and consistent therapeutic effect
- Packaged with desiccant to ensure stability and potency
Benefits
- Effectively increases intestinal absorption of dietary calcium, reducing hypocalcemia risk
- Promotes normal bone mineralization and remodeling, preventing osteodystrophy
- Helps regulate parathyroid hormone (PTH) levels in renal impairment
- Supports musculoskeletal health and reduces fracture risk in vulnerable populations
- Provides a reliable alternative in patients with impaired renal Vitamin D activation
- Contributes to overall metabolic stability in chronic conditions
Common use
Alfacip is primarily prescribed for the management of hypocalcemia and secondary hyperparathyroidism in patients with chronic kidney disease (CKD stages 3-5), particularly those undergoing dialysis. It is also used in the treatment of hypoparathyroidism (post-surgical, idiopathic, or pseudohypoparathyroidism) and in certain cases of vitamin D-dependent rickets. The medication may be utilized off-label in other conditions characterized by calcitriol deficiency or resistance, under specialist supervision.
Dosage and direction
Dosage must be individualized based on disease severity, serum calcium levels, and patient response. For hypocalcemia in dialysis patients: initial dose typically ranges from 0.25 mcg/day to 0.5 mcg/day, with adjustments in 0.25 mcg increments at 2-4 week intervals. For hypoparathyroidism: initial dose is usually 0.25 mcg/day, with titration based on calcium levels. Administration should occur with meals to enhance absorption. Regular monitoring of serum calcium, phosphorus, and creatinine is essential during treatment. Capsules should be swallowed whole with water and not crushed or chewed.
Precautions
Patients should maintain adequate hydration unless contraindicated. Dietary calcium intake should be consistent and monitored—excessive intake may predispose to hypercalcemia. Use with caution in patients with history of renal stones, cardiac disease, or granulomatous disorders. Pregnancy Category C: use only if potential benefit justifies potential risk to fetus. Nursing mothers should exercise caution as calcitriol is excreted in breast milk. Pediatric and geriatric patients may require dosage adjustments and closer monitoring.
Contraindications
Alfacip is contraindicated in patients with hypercalcemia or vitamin D toxicity. It should not be used in patients with known hypersensitivity to calcitriol or any component of the formulation. Contraindicated in patients with evidence of metastatic calcification or hyperphosphatemia (unless adequately controlled). Not recommended for patients with malabsorption syndromes that may affect Vitamin D absorption without careful monitoring.
Possible side effects
Common side effects may include hypercalcemia (manifesting as nausea, vomiting, constipation, weakness), hypercalciuria, and elevated serum creatinine. Less frequently, patients may experience headache, somnolence, or dry mouth. Rare but serious adverse effects include pancreatitis, photophobia, rhinorrhea, and metastatic calcification. Persistent hypercalcemia may lead to renal impairment or cardiac arrhythmias. Patients should report any unusual symptoms, especially those suggestive of elevated calcium levels.
Drug interaction
Alfacip may interact with thiazide diuretics (increased hypercalcemia risk), magnesium-containing antacids (risk of hypermagnesemia), and digitalis glycosides (potential for cardiac arrhythmias). Cholestyramine and mineral oil may reduce absorption. Concurrent use with CYP3A4 inducers (e.g., phenytoin, rifampin) may reduce efficacy. Calcium supplements and phosphate binders should be used with careful monitoring. Corticosteroids may antagonize Vitamin D effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule and contact your healthcare provider if multiple doses are missed, as dosage adjustments or monitoring may be required.
Overdose
Vitamin D intoxication manifests as hypercalcemia, hypercalciuria, and hyperphosphatemia. Symptoms include nausea, vomiting, constipation, weakness, confusion, and cardiac arrhythmias. Treatment involves immediate discontinuation, low-calcium diet, hydration, and monitoring of electrolyte levels. Severe cases may require hospitalization with intravenous fluids, loop diuretics, glucocorticoids, or bisphosphonates. Dialysis against calcium-free dialysate may be necessary in renal impairment.
Storage
Store at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep in original container, tightly closed, and protected from light and moisture. Do not freeze. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Alfacip is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Dosage and treatment duration should be determined based on individual patient needs and laboratory parameters. Always follow your physician’s instructions and report any adverse effects promptly.
Reviews
“After six months on Alfacip, my calcium levels have stabilized for the first time in years. The dosage adjustment process required careful monitoring, but the results have been remarkable.” — Renal patient, 54
“As a nephrologist, I find Alfacip provides predictable control of secondary hyperparathyroidism in my dialysis patients. The capsule formulation ensures consistent dosing and patient compliance.” — Specialist physician
“Managing my son’s hypoparathyroidism became significantly easier with Alfacip. The clear dosing guidelines and regular monitoring have prevented hospitalizations for hypocalcemic episodes.” — Parent of pediatric patient